Essex Woodlands Establishes Shanghai Presence
This article was originally published in Start Up
Essex Woodlands, the large growth equity and venture capital player, became the latest US-based venture capital firm to officially enter the China market by opening an office in Shanghai. The firm joins the community of Kleiner Perkins Caufield & Byers, Orbimed Advisors, Vivo Ventures, and Warburg Pincus LLC, which have offices in the city.
You may also be interested in...
Funded initially in 1996 by private and government sources in Taiwan, Vivo Ventures has emerged as a leader among US-based VCs investing in China. The firm’s partners say its success will come through an intricate web of business development and licensing arrangements between health care companies in China with their counterparts in the US. The strategy has produced results. In the US, specialty pharmaceutical company Sagent Pharmaceuticals went public last year after building a booming business at least partially upon arrangements with China suppliers. In China, Medtronic stepped up in October to acquire Kanghui Medical, an orthopedics company with global vision and connections to privately held US companies.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.